Trials / Completed
CompletedNCT05523596
A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults
A Phase 1 Non-Randomized Open Label Study of ICM20
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- IC-MedTech Corporation · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1 Non-Randomized Open Label Study of Oral ICM20
Detailed description
This is a Phase 1 open label study to access the safety and tolerability of ICM20 alone and in combination with benznidazole
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICM20 | small molecules |
| DRUG | Benznidazole | small molecule |
Timeline
- Start date
- 2023-08-20
- Primary completion
- 2025-10-03
- Completion
- 2025-10-03
- First posted
- 2022-08-31
- Last updated
- 2026-04-16
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05523596. Inclusion in this directory is not an endorsement.